B. Riley raised the firm’s price target on Koru Medical (KRMD) to $8 from $7 and keeps a Buy rating on the shares. Following the Q4 earnings report, B. Riley is “encouraged” by the continued execution across all three of its strategic pillars, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD: